JPWO2019184886A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019184886A5 JPWO2019184886A5 JP2020550874A JP2020550874A JPWO2019184886A5 JP WO2019184886 A5 JPWO2019184886 A5 JP WO2019184886A5 JP 2020550874 A JP2020550874 A JP 2020550874A JP 2020550874 A JP2020550874 A JP 2020550874A JP WO2019184886 A5 JPWO2019184886 A5 JP WO2019184886A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- seq
- sequence represented
- density lipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 318
- 239000012634 fragment Substances 0.000 claims description 64
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 210000002865 immune cell Anatomy 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 49
- 230000008685 targeting Effects 0.000 claims description 34
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 31
- 230000000139 costimulatory effect Effects 0.000 claims description 17
- 230000003834 intracellular effect Effects 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 10
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 10
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 10
- 102100032530 Glypican-3 Human genes 0.000 claims description 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 10
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 10
- 102000003735 Mesothelin Human genes 0.000 claims description 10
- 108090000015 Mesothelin Proteins 0.000 claims description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 5
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims 23
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 8
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 claims 8
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 claims 8
- 102000001774 Low Density Lipoprotein Receptor-Related Protein-6 Human genes 0.000 claims 8
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 claims 8
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102100030704 Interleukin-21 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- -1 HER family members Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810251875.7 | 2018-03-26 | ||
| CN201810251875 | 2018-03-26 | ||
| PCT/CN2019/079576 WO2019184886A1 (zh) | 2018-03-26 | 2019-03-25 | 促进免疫细胞增殖的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021518149A JP2021518149A (ja) | 2021-08-02 |
| JPWO2019184886A5 true JPWO2019184886A5 (da) | 2024-04-16 |
Family
ID=68059463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550874A Pending JP2021518149A (ja) | 2018-03-26 | 2019-03-25 | 免疫細胞増殖を促進する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12005080B2 (da) |
| EP (1) | EP3778876A4 (da) |
| JP (1) | JP2021518149A (da) |
| CN (1) | CN111918964A (da) |
| WO (1) | WO2019184886A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024517719A (ja) * | 2021-04-27 | 2024-04-23 | オリセル セラピューティクス カンパニー リミテッド | Ｂｃｍａを標的としたキメラ型抗原受容体及びその応用 |
| CN116656614A (zh) * | 2022-02-17 | 2023-08-29 | 杭州乾合细胞生物科技有限公司 | 一种靶向Her-2的CAR-NK细胞及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3169703B2 (en) * | 2014-07-16 | 2023-12-13 | Hinrich Abken | Chimeric antigen receptor and its use |
| AU2016317726B2 (en) * | 2015-08-28 | 2022-05-26 | Serpin Pharma, Llc | Methods for treatment of diseases |
| GB201516972D0 (en) | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells |
| WO2017070395A1 (en) * | 2015-10-20 | 2017-04-27 | Kite Pharma, Inc. | Methods of preparing t cells for t cell therapy |
| WO2018009972A1 (en) * | 2016-07-14 | 2018-01-18 | Peter Maccallum Cancer Institute | Chimeric antigen receptor modified t cells |
| EP3600418A4 (en) * | 2017-03-24 | 2021-01-13 | Yale University | LOW DENSITY LIPOPROTEIN RECEPTOR-BOUND PROTEIN-5 INHIBITION WHICH SUPPRESSES TUMOR FORMATION |
| CN108392492B (zh) * | 2017-12-28 | 2021-01-01 | 中国人民解放军第二军医大学东方肝胆外科医院 | Ldlr过表达在nk细胞过继治疗中的应用 |
-
2019
- 2019-03-25 US US17/040,865 patent/US12005080B2/en active Active
- 2019-03-25 JP JP2020550874A patent/JP2021518149A/ja active Pending
- 2019-03-25 EP EP19776983.9A patent/EP3778876A4/en active Pending
- 2019-03-25 WO PCT/CN2019/079576 patent/WO2019184886A1/zh unknown
- 2019-03-25 CN CN201980022452.0A patent/CN111918964A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102110187B1 (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
| US11034763B2 (en) | Flag tagged CD19-CAR-T cells | |
| CN111566124A (zh) | 制备表达嵌合抗原受体的细胞的方法 | |
| CN112074279B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| KR20220145374A (ko) | 신규 키메라 항원 수용체 및 그 용도 | |
| US20200399393A1 (en) | Dimeric Antigen Receptors | |
| CN109069537A (zh) | 共刺激结构域中具有重复结合基序的car | |
| US11725053B2 (en) | Chimeric antigen receptors comprising a human transferrin epitope sequence | |
| WO2018132695A1 (en) | Chimeric antigen receptors targeting tim-1 | |
| CN111836827B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
| US20210015870A1 (en) | Bcma-car-t cells | |
| CN113423726A (zh) | 为过继细胞治疗提供靶向共刺激的受体 | |
| WO2013063419A2 (en) | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting | |
| WO2019192526A1 (zh) | 嵌合抗原受体和其治疗癌症的方法 | |
| WO2021027785A1 (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| JP2022528024A (ja) | Ｃａｒを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 | |
| WO2020172641A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| US20210087249A1 (en) | Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer | |
| WO2020009868A1 (en) | Anti-slamf7 chimeric antigen receptors | |
| CN112204135A (zh) | 一种表达cd3抗体受体复合物的免疫细胞及其用途 | |
| JPWO2019184886A5 (da) | ||
| CN105802975B (zh) | 靶向her2阳性肿瘤的细胞制备物及其用途 | |
| CN115996733A (zh) | 用于免疫疗法的基因工程化γδT细胞 | |
| Khaleghi et al. | Synthesis of chimeric T cell receptor with OX40 co-stimulatory receptor targeted against breast cancer cells | |
| WO2021188454A1 (en) | Engineered cell compositions and methods of use thereof |